Trials / Completed
CompletedNCT00105937
OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
Multi-center, Open Label, Long-term Study of OraVescent Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- Cephalon · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety and efficacy of OraVescent fentanyl to treat breakthrough pain episodes in cancer patients who are already opioid tolerant.
Detailed description
The objective of this study is to determine the tolerability and safety of OraVescent fentanyl when used long term to relieve breakthrough pain in opioid tolerant cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OraVescent fentanyl citrate |
Timeline
- Start date
- 2004-04-01
- Completion
- 2006-11-01
- First posted
- 2005-03-21
- Last updated
- 2012-06-29
Locations
43 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00105937. Inclusion in this directory is not an endorsement.